US HB421 | 2017-2018 | 115th Congress
Status
Sponsorship: Partisan Bill (Republican 16)
Status: Introduced on January 10 2017 - 25% progression, died in committee
Action: 2017-01-26 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on January 10 2017 - 25% progression, died in committee
Action: 2017-01-26 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Allowing Greater Access to Safe and Effective Contraception Act This bill requires the Food and Drug Administration (FDA) to prioritize review of supplemental drug applications (applications to modify the approved use of a drug) for contraceptive drugs intended for routine use that would be available to individuals aged 18 and older without a prescription. The FDA must waive user fees for such supplemental drug applications. Any drug that is eligible for this priority review must be a prescription drug for individuals under age 18. This bill repeals provisions of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 to allow health savings accounts and health flexible spending accounts (HFSAs) to be used to pay for medicine without a prescription and to remove the limit on salary reduction contributions to a HFSA under a cafeteria plan, effective as if the provisions had never been enacted.
Title
Allowing Greater Access to Safe and Effective Contraception Act
Sponsors
| Rep. Mia Love [R-UT] | Rep. Barbara Comstock [R-VA] | Rep. Chris Stewart [R-UT] | Rep. Mike Coffman [R-CO] |
| Rep. Adam Kinzinger [R-IL] | Rep. David Young [R-IA] | Rep. Don Bacon [R-NE] | Rep. Doug LaMalfa [R-CA] |
| Rep. John Faso [R-NY] | Sen. Martha McSally [R-AZ] | Rep. Thomas Garrett [R-VA] | Rep. Jaime Herrera Beutler [R-WA] |
| Rep. Jason Chaffetz [R-UT] | Rep. Elise Stefanik [R-NY] | Sen. John Curtis [R-UT] | Rep. Darrell Issa [R-CA] |
History
| Date | Chamber | Action |
|---|---|---|
| 2017-01-26 | House | Referred to the Subcommittee on Health. |
| 2017-01-25 | House | Referred to the Subcommittee on Health. |
| 2017-01-10 | House | Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
| 2017-01-10 | House | Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
| 2017-01-10 | House | Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
| 2017-01-10 | House | Introduced in House |
Same As/Similar To
SB93 (Same As) 2017-01-10 - Read twice and referred to the Committee on Finance.
Subjects
Drug safety, medical device, and laboratory regulation
Employee benefits and pensions
Family planning and birth control
Health
Health care costs and insurance
Prescription drugs
User charges and fees
Employee benefits and pensions
Family planning and birth control
Health
Health care costs and insurance
Prescription drugs
User charges and fees
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/115th-congress/house-bill/421/all-info |
| Text | https://www.congress.gov/115/bills/hr421/BILLS-115hr421ih.pdf |
